Revenue - Schedule of Licensing, Royalties, and Other (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue Recognition
Total revenue	$ 56,698	$ 239,240	$ 196,212	$ 905,895
Takeda
Revenue Recognition
Upfront payments	14,500		14,500
Unrecongnized consideration			4,000
Licensing, royalties, and other
Revenue Recognition
Total revenue	37,844	228,516	135,158	273,493
Database lock of an Existing Phase 2/3 clinical trial
Revenue Recognition
Upfront fee and milestones			500,000
Development, tech transfer, launch, and sales milestone payments			50,000
Sanofi \| Licensing, royalties, and other
Revenue Recognition
Total revenue	35,768	199,412	84,666	239,733
Sanofi \| Milestones
Revenue Recognition
Total revenue	0	175,000	0	175,000
Sanofi \| Royalties
Revenue Recognition
Total revenue	676	0	4,195	0
Sanofi \| Upfront fee amortization
Revenue Recognition
Total revenue	8,728	12,268	20,834	32,180
Sanofi \| Milestones amortization
Revenue Recognition
Total revenue	3,762	5,665	9,313	14,808
Sanofi \| Cost reimbursements
Revenue Recognition
Total revenue	22,602	6,479	50,324	17,745
Pfizer \| Licensing, royalties, and other
Revenue Recognition
Total revenue	0	0	30,000	0
Takeda \| Licensing, royalties, and other
Revenue Recognition
Total revenue	215	27,212	950	27,212
Serum \| Licensing, royalties, and other
Revenue Recognition
Total revenue	1,823	1,892	9,189	6,548
Other partners \| Licensing, royalties, and other
Revenue Recognition
Total revenue	38	0	10,353	0
Takeda \| Licensing, royalties, and other
Revenue Recognition
Total revenue	215	27,212	950	27,212
Takeda \| Upfront fee
Revenue Recognition
Total revenue	0	18,500	0	18,500
Takeda \| Milestones
Revenue Recognition
Total revenue	0	3,434	0	3,434
Takeda \| Royalties
Revenue Recognition
Total revenue	(50)	5,000	611	5,000
Takeda \| Support services
Revenue Recognition
Total revenue	$ 265	$ 278	$ 339	$ 278